These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22214655)

  • 1. The disintegration behaviour of capsules in fed subjects: a comparison of hypromellose (carrageenan) capsules and standard gelatin capsules.
    Jones BE; Basit AW; Tuleu C
    Int J Pharm; 2012 Mar; 424(1-2):40-3. PubMed ID: 22214655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A scintigraphic investigation of the disintegration behaviour of capsules in fasting subjects: a comparison of hypromellose capsules containing carrageenan as a gelling agent and standard gelatin capsules.
    Tuleu C; Khela MK; Evans DF; Jones BE; Nagata S; Basit AW
    Eur J Pharm Sci; 2007 Mar; 30(3-4):251-5. PubMed ID: 17188473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo pharmacoscintigraphic evaluation of ibuprofen hypromellose and gelatin capsules.
    Cole ET; Scott RA; Cade D; Connor AL; Wilding IR
    Pharm Res; 2004 May; 21(5):793-8. PubMed ID: 15180336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the human in vivo performance of different oral capsule shell types using a novel in vitro dynamic gastric model.
    Vardakou M; Mercuri A; Naylor TA; Rizzo D; Butler JM; Connolly PC; Wickham MS; Faulks RM
    Int J Pharm; 2011 Oct; 419(1-2):192-9. PubMed ID: 21843611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules.
    Curatolo W; Liu P; Johnson BA; Hausberger A; Quan E; Vendola T; Vatsaraj N; Foulds G; Vincent J; Chandra R
    Pharm Res; 2011 Jul; 28(7):1531-9. PubMed ID: 21331473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance qualification of a new hypromellose capsule: part I. Comparative evaluation of physical, mechanical and processability quality attributes of Vcaps Plus, Quali-V and gelatin capsules.
    Sherry Ku M; Li W; Dulin W; Donahue F; Cade D; Benameur H; Hutchison K
    Int J Pharm; 2010 Feb; 386(1-2):30-41. PubMed ID: 19900518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability and in vitro oesophageal sticking tendency of hydroxypropyl methylcellulose capsule formulations and corresponding gelatine capsule formulations.
    Honkanen O; Laaksonen P; Marvola J; Eerikäinen S; Tuominen R; Marvola M
    Eur J Pharm Sci; 2002 Jun; 15(5):479-88. PubMed ID: 12036724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance qualification of a new hypromellose capsule: Part II. Disintegration and dissolution comparison between two types of hypromellose capsules.
    Ku MS; Lu Q; Li W; Chen Y
    Int J Pharm; 2011 Sep; 416(1):16-24. PubMed ID: 21356291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and comparison of physicomechanical characteristics of gelatin and hypromellose capsules.
    Missaghi S; Fassihi R
    Drug Dev Ind Pharm; 2006 Aug; 32(7):829-38. PubMed ID: 16908420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma scintigraphic evaluation of the fate of hydroxypropyl methylcellulose capsules in the human gastrointestinal tract.
    Honkanen O; Marvola J; Kanerva H; Lindevall K; Lipponen M; Kekki T; Ahonen A; Marvola M
    Eur J Pharm Sci; 2004 Apr; 21(5):671-8. PubMed ID: 15066668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of capsule shell composition on the performance indicators of hypromellose capsule in comparison to hard gelatin capsules.
    Al-Tabakha MM; Arida AI; Fahelelbom KM; Sadek B; Saeed DA; Abu Jarad RA; Jawadi J
    Drug Dev Ind Pharm; 2015; 41(10):1726-37. PubMed ID: 25586554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified conventional hard gelatin capsules as fast disintegrating dosage form in the oral cavity.
    Ciper M; Bodmeier R
    Eur J Pharm Biopharm; 2006 Feb; 62(2):178-84. PubMed ID: 16260126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hard gelatin and hypromellose (HPMC) capsules: estimation of rupture time by real-time dissolution spectroscopy.
    El-Malah Y; Nazzal S; Bottom CB
    Drug Dev Ind Pharm; 2007 Jan; 33(1):27-34. PubMed ID: 17192248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.
    Ouellet D; Grossmann KF; Limentani G; Nebot N; Lan K; Knowles L; Gordon MS; Sharma S; Infante JR; Lorusso PM; Pande G; Krachey EC; Blackman SC; Carson SW
    J Pharm Sci; 2013 Sep; 102(9):3100-9. PubMed ID: 23608920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vitro dissolution of theophylline from different types of hard shell capsules.
    Podczeck F; Jones BE
    Drug Dev Ind Pharm; 2002 Oct; 28(9):1163-9. PubMed ID: 12455475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scintigraphic study to investigate the effect of food on a HPMC modified release formulation of UK-294,315.
    Davis J; Burton J; Connor AL; Macrae R; Wilding IR
    J Pharm Sci; 2009 Apr; 98(4):1568-76. PubMed ID: 18752268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects.
    Greaves JL; Wilson CG; Birmingham AT
    Br J Clin Pharmacol; 1993 Feb; 35(2):188-92. PubMed ID: 8443038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The shell dissolution of various empty hard capsules.
    Chiwele I; Jones BE; Podczeck F
    Chem Pharm Bull (Tokyo); 2000 Jul; 48(7):951-6. PubMed ID: 10923822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the puncturing properties of gelatin and hypromellose capsules for use in dry powder inhalers.
    Birchall JC; Jones BE; Morrissey A; Jones BE
    Drug Dev Ind Pharm; 2008 Aug; 34(8):870-6. PubMed ID: 18686093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPMC capsules: current status and future prospects.
    Al-Tabakha MM
    J Pharm Pharm Sci; 2010; 13(3):428-42. PubMed ID: 21092714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.